4/30
08:17 am
rgls
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series [Yahoo! Finance]
High
Report
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series [Yahoo! Finance]
4/30
08:00 am
rgls
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
Medium
Report
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
4/16
07:45 am
rgls
Global Antisense and RNAi Therapeutics Report 2024: A USD 34.7 Billion Predicted Market by 2034, with CAGR of 18% During 2024-2034 [Yahoo! Finance]
Medium
Report
Global Antisense and RNAi Therapeutics Report 2024: A USD 34.7 Billion Predicted Market by 2034, with CAGR of 18% During 2024-2034 [Yahoo! Finance]
4/16
02:08 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
4/10
01:21 pm
rgls
Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD [Seeking Alpha]
Low
Report
Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD [Seeking Alpha]
4/8
02:07 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
3/31
02:08 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
3/25
08:07 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
3/23
02:10 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
3/21
04:21 pm
rgls
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates [Yahoo! Finance]
Low
Report
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates [Yahoo! Finance]
3/21
04:05 pm
rgls
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
Low
Report
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
3/19
08:37 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $12.00 to $11.00. They now have a "buy" rating on the stock.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $12.00 to $11.00. They now have a "buy" rating on the stock.
3/19
06:46 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
3/18
03:16 pm
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its price target raised by analysts at Wells Fargo & Company from $2.00 to $3.00. They now have an "equal weight" rating on the stock.
Low
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its price target raised by analysts at Wells Fargo & Company from $2.00 to $3.00. They now have an "equal weight" rating on the stock.
3/18
02:52 pm
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Low
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
3/18
08:19 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $6.00 price target on the stock.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $6.00 price target on the stock.
3/15
02:27 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
3/13
01:32 pm
rgls
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study [Yahoo! Finance]
Medium
Report
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study [Yahoo! Finance]
3/12
06:56 am
rgls
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Yahoo! Finance]
High
Report
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Yahoo! Finance]
3/12
06:39 am
rgls
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity [Yahoo! Finance]
Low
Report
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity [Yahoo! Finance]
3/12
06:32 am
rgls
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
Medium
Report
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
3/12
06:30 am
rgls
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
High
Report
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
3/7
02:07 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
2/28
02:06 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
2/20
02:14 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.